GlassScriptPhysician profile
Charles I Taylor
NPI 1952348948
$4,367.50
in general payments reported to CMS, 2019-2025
43 companies · $19.04 in 2025
The $19.04 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $679 · 2021: $669 · 2022: $1,392 · 2023: $81.57 · 2024: $55.48 · 2025: $19.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $156.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $758.41 | 2019-2023 | Ozempic, Rybelsus |
| Amgen INC. | $627.36 | 2019-2022 | |
| Lilly USA, LLC | $445.69 | 2019-2023 | Mounjaro |
| Merck Sharp & Dohme LLC | $273.48 | 2019-2021 | |
| Abbvie INC. | $202.29 | 2019-2022 | |
| Abbott Laboratories | $146.38 | 2020-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $144.01 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $143.38 | 2019-2022 | |
| Mannkind Corporation | $129.83 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $110.43 | 2019-2020 | |
| Dexcom, INC. | $108.00 | 2019-2022 | |
| Insulet Corporation | $74.75 | 2019 | |
| Radius Health, INC. | $72.54 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.43 | 2021-2022 | |
| Pfizer INC. | $67.49 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.